{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:55:02Z","timestamp":1785884102172,"version":"3.56.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T00:00:00Z","timestamp":1644624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T00:00:00Z","timestamp":1644624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00277-022-04784-0","type":"journal-article","created":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T01:02:30Z","timestamp":1644627750000},"page":"953-961","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparative efficacy of 19 drug therapies for patients with idiopathic thrombocytopenic purpura: a multiple-treatments network meta-analysis"],"prefix":"10.1007","volume":"101","author":[{"given":"Huifeng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3105-4362","authenticated-orcid":false,"given":"Shaoyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,12]]},"reference":[{"issue":"11","key":"4784_CR1","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","volume":"113","author":"F Rodeghiero","year":"2009","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kuhne T, Ruggeri M, George JN (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113(11):2386\u20132393. https:\/\/doi.org\/10.1182\/blood-2008-07-162503","journal-title":"Blood"},{"issue":"12","key":"4784_CR2","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.3324\/haematol.2011.055830","volume":"96","author":"H Schulze","year":"2011","unstructured":"Schulze H, Gaedicke G (2011) Immune thrombocytopenia in children and adults: what\u2019s the same, what\u2019s different? Haematologica 96(12):1739\u20131741. https:\/\/doi.org\/10.3324\/haematol.2011.055830","journal-title":"Haematologica"},{"issue":"5","key":"4784_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/MOH.0000000000000270","volume":"23","author":"A Cuker","year":"2016","unstructured":"Cuker A, Cines DB, Neunert CE (2016) Controversies in the treatment of immune thrombocytopenia. Curr Opin Hematol 23(5):479\u2013485. https:\/\/doi.org\/10.1097\/MOH.0000000000000270","journal-title":"Curr Opin Hematol"},{"issue":"14","key":"4784_CR4","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1182\/blood-2009-07-229815","volume":"115","author":"F Zaja","year":"2010","unstructured":"Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, Vianelli N, Defina M, Tieghi A, Amadori S, Campagna S, Ferrara F, Angelucci E, Usala E, Cantoni S, Visani G, Fornaro A, Rizzi R, De Stefano V, Casulli F, Battista ML, Isola M, Soldano F, Gamba E, Fanin R (2010) Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 115(14):2755\u20132762. https:\/\/doi.org\/10.1182\/blood-2009-07-229815","journal-title":"Blood"},{"issue":"11","key":"4784_CR5","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1182\/blood-2012-09-455691","volume":"121","author":"S Gudbrandsdottir","year":"2013","unstructured":"Gudbrandsdottir S, Birgens HS, Frederiksen H, Jensen BA, Jensen MK, Kjeldsen L, Klausen TW, Larsen H, Mourits-Andersen HT, Nielsen CH, Nielsen OJ, Plesner T, Pulczynski S, Rasmussen IH, Ronnov-Jessen D, Hasselbalch HC (2013) Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood 121(11):1976\u20131981. https:\/\/doi.org\/10.1182\/blood-2012-09-455691","journal-title":"Blood"},{"issue":"8","key":"4784_CR6","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/S2352-3026(15)00114-3","volume":"2","author":"JB Bussel","year":"2015","unstructured":"Bussel JB, de Miguel PG, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS, Krishnamurti L, Connor P, David M, Boayue KB, Matthews DC, Lambert MP, Marcello LM, Iyengar M, Chan GW, Chagin KD, Theodore D, Bailey CK, Bakshi KK (2015) Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol 2(8):e315-325. https:\/\/doi.org\/10.1016\/S2352-3026(15)00114-3","journal-title":"Lancet Haematol"},{"issue":"4","key":"4784_CR7","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1016\/S2352-3026(21)00030-2","volume":"8","author":"L Sun","year":"2021","unstructured":"Sun L, Wang J, Shao L, Yuan C, Zhao H, Li D, Wang Z, Han P, Yu Y, Xu M, Zhao H, Qiu J, Zhou H, Liu X, Hou Y, Peng J, Hou M (2021) Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. Lancet Haematol 8(4):e289\u2013e298. https:\/\/doi.org\/10.1016\/S2352-3026(21)00030-2","journal-title":"Lancet Haematol"},{"issue":"3","key":"4784_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/0962280207080643","volume":"17","author":"G Salanti","year":"2008","unstructured":"Salanti G, Higgins JP, Ades AE, Ioannidis JP (2008) Evaluation of networks of randomized trials. Stat Methods Med Res 17(3):279\u2013301. https:\/\/doi.org\/10.1177\/0962280207080643","journal-title":"Stat Methods Med Res"},{"issue":"1\u20133","key":"4784_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.schres.2009.07.012","volume":"114","author":"CJ Bushe","year":"2009","unstructured":"Bushe CJ, Bradley AJ, Wildgust HJ, Hodgson RE (2009) Schizophrenia and breast cancer incidence: a systematic review of clinical studies. Schizophr Res 114(1\u20133):6\u201316. https:\/\/doi.org\/10.1016\/j.schres.2009.07.012","journal-title":"Schizophr Res"},{"issue":"7132","key":"4784_CR10","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1136\/bmj.316.7132.690","volume":"316","author":"GH Guyatt","year":"1998","unstructured":"Guyatt GH, Juniper EF, Walter SD, Griffith LE, Goldstein RS (1998) Interpreting treatment effects in randomised trials. BMJ 316(7132):690\u2013693. https:\/\/doi.org\/10.1136\/bmj.316.7132.690","journal-title":"BMJ"},{"issue":"3","key":"4784_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177\u2013188. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2","journal-title":"Control Clin Trials"},{"issue":"1","key":"4784_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1017\/S1121189X00004577","volume":"16","author":"A Cipriani","year":"2007","unstructured":"Cipriani A, Nose M, Barbui C (2007) What is a risk ratio? Epidemiol Psichiatr Soc 16(1):20\u201321","journal-title":"Epidemiol Psichiatr Soc"},{"issue":"7414","key":"4784_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"issue":"7","key":"4784_CR14","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1002\/pbc.25984","volume":"63","author":"SD Mathias","year":"2016","unstructured":"Mathias SD, Li X, Eisen M, Carpenter N, Crosby RD, Blanchette VS (2016) A phase 3, randomized, double-blind, placebo-controlled study to determine the effect of romiplostim on health-related quality of life in children with primary immune thrombocytopenia and associated burden in their parents. Pediatr Blood Cancer 63(7):1232\u20131237. https:\/\/doi.org\/10.1002\/pbc.25984","journal-title":"Pediatr Blood Cancer"},{"issue":"10039","key":"4784_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0140-6736(16)00279-8","volume":"388","author":"MD Tarantino","year":"2016","unstructured":"Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M (2016) Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet 388(10039):45\u201354. https:\/\/doi.org\/10.1016\/S0140-6736(16)00279-8","journal-title":"Lancet"},{"issue":"7","key":"4784_CR16","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/ajh.25479","volume":"94","author":"RF Grace","year":"2019","unstructured":"Grace RF, Shimano KA, Bhat R, Neunert C, Bussel JB, Klaassen RJ, Lambert MP, Rothman JA, Breakey VR, Hege K, Bennett CM, Rose MJ, Haley KM, Buchanan GR, Geddis A, Lorenzana A, Jeng M, Pastore YD, Crary SE, Neier M, Neufeld EJ, Neu N, Forbes PW, Despotovic JM (2019) Second-line treatments in children with immune thrombocytopenia: effect on platelet count and patient-centered outcomes. Am J Hematol 94(7):741\u2013750. https:\/\/doi.org\/10.1002\/ajh.25479","journal-title":"Am J Hematol"},{"issue":"3","key":"4784_CR17","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/bjh.15803","volume":"185","author":"DJ Kuter","year":"2019","unstructured":"Kuter DJ, Newland A, Chong BH, Rodeghiero F, Romero MT, Pabinger I, Chen Y, Wang K, Mehta B, Eisen M (2019) Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. Br J Haematol 185(3):503\u2013513. https:\/\/doi.org\/10.1111\/bjh.15803","journal-title":"Br J Haematol"},{"issue":"3","key":"4784_CR18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/bjh.15573","volume":"183","author":"W Jurczak","year":"2018","unstructured":"Jurczak W, Chojnowski K, Mayer J, Krawczyk K, Jamieson BD, Tian W, Allen LF (2018) Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol 183(3):479\u2013490. https:\/\/doi.org\/10.1111\/bjh.15573","journal-title":"Br J Haematol"},{"issue":"10004","key":"4784_CR19","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/S0140-6736(15)61107-2","volume":"386","author":"JD Grainger","year":"2015","unstructured":"Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, Lebedev V, Lemons R, Pospisilova D, Ramenghi U, Bussel JB, Bakshi KK, Iyengar M, Chan GW, Chagin KD, Theodore D, Marcello LM, Bailey CK (2015) Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet 386(10004):1649\u20131658. https:\/\/doi.org\/10.1016\/S0140-6736(15)61107-2","journal-title":"Lancet"},{"issue":"2","key":"4784_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/ajh.25680","volume":"95","author":"AC Newland","year":"2020","unstructured":"Newland AC, Sanchez-Gonzalez B, Rejto L, Egyed M, Romanyuk N, Godar M, Verschueren K, Gandini D, Ulrichts P, Beauchamp J, Dreier T, Ward ES, Michel M, Liebman HA, de Haard H, Leupin N, Kuter DJ (2020) Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Am J Hematol 95(2):178\u2013187. https:\/\/doi.org\/10.1002\/ajh.25680","journal-title":"Am J Hematol"},{"issue":"9978","key":"4784_CR21","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/S0140-6736(14)61495-1","volume":"385","author":"W Ghanima","year":"2015","unstructured":"Ghanima W, Khelif A, Waage A, Michel M, Tjonnfjord GE, Romdhan NB, Kahrs J, Darne B, Holme PA, group Rs, (2015) Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 385(9978):1653\u20131661. https:\/\/doi.org\/10.1016\/S0140-6736(14)61495-1","journal-title":"Lancet"},{"issue":"3","key":"4784_CR22","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.3324\/haematol.2014.110213","volume":"100","author":"JJ Zwaginga","year":"2015","unstructured":"Zwaginga JJ, van der Holt B, Te Boekhorst PA, Biemond BJ, Levin MD, van der Griend R, Brand A, Zweegman S, Pruijt HF, Novotny VM, Vreugdenhil A, de Groot MR, de Weerdt O, van Pampus EC, van Maanen-Lamme TM, Wittebol S, Schipperus MR, Silbermann MH, Huijgens PC, Luten M, Hollestein R, Brakenhoff JA, Schrama JG, Valster FA, Velders GA, Koene HR, Hsg D (2015) Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients. Haematologica 100(3):e90-92. https:\/\/doi.org\/10.3324\/haematol.2014.110213","journal-title":"Haematologica"},{"issue":"9","key":"4784_CR23","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1182\/blood-2018-02-830844","volume":"132","author":"KMJ Heitink-Polle","year":"2018","unstructured":"Heitink-Polle KMJ, Uiterwaal C, Porcelijn L, Tamminga RYJ, Smiers FJ, van Woerden NL, Wesseling J, Vidarsson G, Laarhoven AG, de Haas M, Bruin MCA, Investigators T (2018) Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial. Blood 132(9):883\u2013891. https:\/\/doi.org\/10.1182\/blood-2018-02-830844","journal-title":"Blood"},{"issue":"12","key":"4784_CR24","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1002\/ajh.25989","volume":"95","author":"Y Yu","year":"2020","unstructured":"Yu Y, Wang M, Hou Y, Qin P, Zeng Q, Yu W, Guo X, Wang J, Wang X, Liu G, Chu X, Yang L, Feng Y, Zhou F, Sun Z, Zhang M, Wang X, Wang Z, Ran X, Zhao H, Wang L, Zhang H, Bi K, Li D, Yuan C, Xu R, Wang Y, Zhou Y, Peng J, Liu XG, Hou M (2020) High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: a prospective, multicenter, randomized trial. Am J Hematol 95(12):1542\u20131552. https:\/\/doi.org\/10.1002\/ajh.25989","journal-title":"Am J Hematol"},{"key":"4784_CR25","doi-asserted-by":"publisher","unstructured":"Wei Y, Ji XB, Wang YW, Wang JX, Yang EQ, Wang ZC, Sang YQ, Bi ZM, Ren CA, Zhou F, Liu GQ, Peng J, Hou M (2016) High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood 127 (3):296\u2013302; quiz 370. https:\/\/doi.org\/10.1182\/blood-2015-07-659656","DOI":"10.1182\/blood-2015-07-659656"},{"issue":"10","key":"4784_CR26","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1182\/blood-2014-06-581868","volume":"125","author":"H Zhou","year":"2015","unstructured":"Zhou H, Xu M, Qin P, Zhang HY, Yuan CL, Zhao HG, Cui ZG, Meng YS, Wang L, Zhou F, Wang X, Li DQ, Bi KH, Zhu CS, Guo CS, Chu XX, Wu QC, Liu XG, Dong XY, Li J, Peng J, Hou M (2015) A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP. Blood 125(10):1541\u20131547. https:\/\/doi.org\/10.1182\/blood-2014-06-581868","journal-title":"Blood"},{"issue":"6","key":"4784_CR27","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1177\/1076029618764843","volume":"24","author":"A Pirunsarn","year":"2018","unstructured":"Pirunsarn A, Kijrattanakul P, Chamnanchanunt S, Polprasert C, Rojnuckarin P (2018) A randomized multicenter trial comparing low-dose prednisolone versus observation for prevention of recurrences in adult immune thrombocytopenia. Clin Appl Thromb Hemost 24(6):867\u2013873. https:\/\/doi.org\/10.1177\/1076029618764843","journal-title":"Clin Appl Thromb Hemost"},{"issue":"11","key":"4784_CR28","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1007\/s00277-020-04257-2","volume":"99","author":"JC Jaime-Perez","year":"2020","unstructured":"Jaime-Perez JC, Aguilar-Calderon P, Jimenez-Castillo RA, Ramos-Davila EM, Salazar-Cavazos L, Gomez-Almaguer D (2020) Treatment outcomes and chronicity predictors for primary immune thrombocytopenia: 10-year data from an academic center. Ann Hematol 99(11):2513\u20132520. https:\/\/doi.org\/10.1007\/s00277-020-04257-2","journal-title":"Ann Hematol"},{"issue":"7","key":"4784_CR29","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ajh.25125","volume":"93","author":"J Bussel","year":"2018","unstructured":"Bussel J, Arnold DM, Grossbard E, Mayer J, Trelinski J, Homenda W, Hellmann A, Windyga J, Sivcheva L, Khalafallah AA, Zaja F, Cooper N, Markovtsov V, Zayed H, Duliege AM (2018) Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol 93(7):921\u2013930. https:\/\/doi.org\/10.1002\/ajh.25125","journal-title":"Am J Hematol"},{"issue":"4","key":"4784_CR30","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3109\/09537104.2014.911836","volume":"26","author":"HS Brito","year":"2015","unstructured":"Brito HS, Braga JA, Loggetto SR, Machado RS, Granato CF, Kawakami E (2015) Helicobacter pylori infection & immune thrombocytopenic purpura in children and adolescents: a randomized controlled trial. Platelets 26(4):336\u2013341. https:\/\/doi.org\/10.3109\/09537104.2014.911836","journal-title":"Platelets"},{"issue":"12","key":"4784_CR31","doi-asserted-by":"publisher","first-page":"E228","DOI":"10.1002\/ajh.23832","volume":"89","author":"WB Mitchell","year":"2014","unstructured":"Mitchell WB, Pinheiro MP, Boulad N, Kaplan D, Edison MN, Psaila B, Karpoff M, White MJ, Josefsson EC, Kile BT, Bussel JB (2014) Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia. Am J Hematol 89(12):E228-234. https:\/\/doi.org\/10.1002\/ajh.23832","journal-title":"Am J Hematol"},{"issue":"9763","key":"4784_CR32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","volume":"377","author":"G Cheng","year":"2011","unstructured":"Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB (2011) Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 377(9763):393\u2013402. https:\/\/doi.org\/10.1016\/S0140-6736(10)60959-2","journal-title":"Lancet"},{"issue":"16","key":"4784_CR33","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","volume":"117","author":"Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Jr., Crowther MA, American Society of H","year":"2011","unstructured":"Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Jr., Crowther MA, American Society of H (2011) The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 117(16):4190\u20134207. https:\/\/doi.org\/10.1182\/blood-2010-08-302984","journal-title":"Blood"},{"issue":"1","key":"4784_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","volume":"146","author":"DM Arnold","year":"2007","unstructured":"Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG (2007) Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 146(1):25\u201333. https:\/\/doi.org\/10.7326\/0003-4819-146-1-200701020-00006","journal-title":"Ann Intern Med"},{"issue":"2","key":"4784_CR35","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1365-2141.2004.04889.x","volume":"125","author":"N Cooper","year":"2004","unstructured":"Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB (2004) The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 125(2):232\u2013239. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.04889.x","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04784-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04784-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04784-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T09:06:17Z","timestamp":1649408777000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04784-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,12]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["4784"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04784-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,12]]},"assertion":[{"value":"5 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Research Ethics Review Committee of Children\u2019s Hospital of Soochow University and conducted following institutional guidelines and Helsinki\u2019s Declaration. Informed consent was obtained from all patients before data collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We have got consent from all the authors for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}